Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.15
- Piotroski Score 2.00
- Grade Neutral
- Symbol (KYTX)
- Company Kyverna Therapeutics, Inc. Common Stock
- Price $4.39
- Changes Percentage (10.03%)
- Change $0.4
- Day Low $3.92
- Day High $4.42
- Year High $30.60
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/25/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.00
- Trailing P/E Ratio N/A
- Forward P/E Ratio N/A
- P/E Growth N/A
- Net Income $-60,366,000
Income Statement
Quarterly
Annual
Latest News of KYTX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
institutional investors of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) must be disappointed after last week's 18% drop
Analyzing ownership data and analyst forecasts provides insights into stock opportunities. Institutional investors hold a 40% stake in Kyverna Therapeutics, impacting stock performance. Understanding ...
By Yahoo! Finance | 6 days ago -
Kyverna Therapeutics (KYTX): Leading Nano Cap with Promising CAR T-Cell Therapy
The article discusses the potential of Kyverna Therapeutics, Inc. as one of the best nano cap stocks to invest in, focusing on its innovative therapies for autoimmune diseases. The company's progress,...
By Yahoo! Finance | 1 month ago -
We Think Kyverna Therapeutics (NASDAQ:KYTX) Can Afford To Drive Business Growth
Investing in unprofitable companies like Amazon can yield profits, but risks exist. Analyzing Kyverna Therapeutics' cash burn, with a 5.5-year cash runway, shows promise. However, the increasing cash ...
By Yahoo! Finance | 3 months ago
